{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:20:43Z","timestamp":1777058443714,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["neuromodulationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromodulation: Technology at the Neural Interface"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1111\/ner.12274","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T01:38:54Z","timestamp":1424741934000},"page":"414-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability"],"prefix":"10.1016","volume":"18","author":[{"given":"Jason E.","family":"Pope","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ner.12274_bib1","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","article-title":"Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/ner.12274_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.36076\/ppj.2011\/14\/219","article-title":"Intrathecal therapy for cancer and noncancer pain","volume":"14","author":"Hayek","year":"2011","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12274_bib3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/ALN.0b013e3181b64ab8","article-title":"Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain","volume":"111","author":"Coffey","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1111\/ner.12274_bib4","doi-asserted-by":"crossref","unstructured":"Pope JE, Deer TR. Ziconotide: a clinical update and pharmacologic review. Expert Opin Pharmacother 2103;14:957\u2013966.","DOI":"10.1517\/14656566.2013.784269"},{"key":"10.1111\/ner.12274_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1525-1403.2012.00479.x","article-title":"Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in dog","volume":"15","author":"Yaksh","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib6","first-page":"1084","article-title":"Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain","volume":"25","author":"Wermeling","year":"2005","journal-title":"Pharmacology"},{"key":"10.1111\/ner.12274_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ner.12003","article-title":"Bolus intrathecal injection of ziconotide (prialt) to evaluate the option of continuous administration via an implanted intrathecal drug delivery system: a pilot study","volume":"16","author":"Mohammed","year":"2013","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","article-title":"A randomized, double-blind, placebo controlled study of intrathecal ziconotide in adults with severe chronic pain","volume":"31","author":"Rauck","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12274_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/ner.12274_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1525-1403.2006.00055.x","article-title":"Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial","volume":"9","author":"Wallace","year":"2006","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpainsymman.2008.02.016","article-title":"Long-term intrathecal ziconotide for chronic pain: an open labeled study","volume":"37","author":"Webster","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12274_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1525-1403.2012.00476.x","article-title":"Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib14","doi-asserted-by":"crossref","unstructured":"Huang KT, Martin J, Marky A et al. National survey of spinal cord stimulation trial-to-permanent conversion. Neuromodulation 2014; e-pub ahead of print. doi:10.1111\/ner.12199","DOI":"10.1111\/ner.12199"},{"key":"10.1111\/ner.12274_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1525-1403.2012.00450.x","article-title":"Polyanalgesic consensus conference\u20132012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1259\/bjr\/66206791","article-title":"Cerebrospinal fluid flow imaging by using phase-contrast MR technique","volume":"84","author":"Battal","year":"2011","journal-title":"Br J Radiol"},{"key":"10.1111\/ner.12274_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.brainresrev.2010.08.002","article-title":"Recent insights into the hydrodymanics of the cerebrospinal fluid","volume":"65","author":"Bulat","year":"2011","journal-title":"Brain Res Rev"},{"key":"10.1111\/ner.12274_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0730-725X(99)00142-3","article-title":"Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis","volume":"18","author":"Henry-Feugeas","year":"2000","journal-title":"Magn Reson Imaging"},{"key":"10.1111\/ner.12274_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.rli.0000112089.66448.bd","article-title":"The influence of pulse and respiration on spinal cerebrospinal fluid pulsation","volume":"39","author":"Friese","year":"2004","journal-title":"Invest Radiol"},{"key":"10.1111\/ner.12274_bib20","first-page":"106","article-title":"Effect of anatomic fine structure on the flow of cerebrospinal fluid in the spinal subarachnoid space","volume":"128","author":"Stockman","year":"2006","journal-title":"J Biochem Eng"},{"key":"10.1111\/ner.12274_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0006-3223(90)90470-M","article-title":"Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid","volume":"27","author":"Degrell","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1111\/ner.12274_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/AAP.0b013e3181fe7f29","article-title":"Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion","volume":"36","author":"Hejtmanek","year":"2011","journal-title":"Reg Anesth Pain Med"},{"key":"10.1111\/ner.12274_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.36076\/ppj.2010\/13\/23","article-title":"Considerations and methodology for trialing ziconotide","volume":"13","author":"Burton","year":"2010","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12274_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1525-1403.2003.03023.x","article-title":"A prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy","volume":"6","author":"Anderson","year":"2003","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12274_bib25","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.36076\/ppj.2010\/13\/E175","article-title":"Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery","volume":"13","author":"Deer","year":"2010","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12274_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2011.10.002","article-title":"Intrathecal combintion of ziconotide and morphine for refractory pin: rapidly acting and an effective choice","volume":"153","author":"Alcino","year":"2012","journal-title":"Pain"},{"key":"10.1111\/ner.12274_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1525-1403.2009.00257.x","article-title":"Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the prometra programmable pump","volume":"2","author":"Rauck","year":"2010","journal-title":"Neuromodulation"}],"container-title":["Neuromodulation: Technology at the Neural Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fner.12274","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715921017189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715921017189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ner.12274\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:52:43Z","timestamp":1761083563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094715921017189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1094715921017189"],"URL":"https:\/\/doi.org\/10.1111\/ner.12274","relation":{},"ISSN":["1094-7159"],"issn-type":[{"value":"1094-7159","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability","name":"articletitle","label":"Article Title"},{"value":"Neuromodulation: Technology at the Neural Interface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ner.12274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}